Biotech Co.*
(Country/Symbol)

Pharma Co. (Country)

Type/Product Area

Disclosed Funding (M)

Terms/Details (Date)


Accelrys
(subsidiary of
Pharmacopeia
Inc.; PCOP)

GlaxoSmith-
Kline plc (UK)

Collaboration to produce software that enables GSK scientists to access, analyze and visualize chemical and biological data

ND

The data are stored on Glaxo's research and development databases (10/25)

Advanced
Tissue
Sciences
Inc.
(ATIS)

Medtronic Inc.

Collaboration to explore how the companies' technologies can work together

$20

A Medtronic affiliate purchased $20M of common stock as part of the partnership; ATS and Medtronic will test ATS's technology in cardiovascular, neurological, endocrinological and spinal areas; Medtronic receives a right of first refusal to develop products and to pursue programs (10/4)

Arakis Ltd.
(UK)*

Penwest
Pharmaceu-
ticals Co.

Three-year alliance to develop up to six orally delivered performance- enhanced medicines for the treatment of pain conditions

ND

The new products will be jointly developed in the clinic during the alliance and will be created by combining Penwest's oral drug delivery capability with Arakis' ability to enhance known pharmacological agents (11/14)

Array
BioPharma
Inc.
(ARRY)
Ltd. (Japan)

Takeda
Chemical
Industries

Agreement to develop small-molecule drug leads

ND

Array could receive milestones, and royalties based on the sales of products from the collaboration (9/20)

Atrix Lab-
oratories
Inc.
(ATRX)

Fujisawa
Healthcare
Inc.

Licensing agreement for North American rights to Atrix's topical acne treatment, Atrisone

$25

Fujisawa will pay Atrix up to $25M in license fees, research and development support and milestone payments; Atrix will manufacture Atrisone and will receive a manufacturing margin, as well as royalties (10/17)

Atugen AG
(Germany)*

AstraZeneca
plc (UK)

One-year collaboration to use Atugen's GeneBloc technology to increase efficiency of target validation and drug development in a number of major disease areas

ND

Atugen will retain all rights to Gene-Blocs developed and will have an option to license intellectual property generated (10/16)

Avant Immun-
otherapeutics
Inc.
(AVAN)

DynPort
Vaccine Co.
LLC (a joint
venture of
DynCorp
and Porton International Inc.)

License agreement giving DynPort Vaccine exclusive rights to use certain components of Avant's vaccine technology

ND

DynPort will advance the development of vaccines and other products for the government to protect against biological warfare agents; Avant is entitled to license fees, milestones and royalties (10/10)

BioLeads
GmbH
(Germany)*

Schering AG
(Germany)

Research and license agreement related to potential drug compounds derived from microbial strains

ND

BioLeads plans to provide pre-purified subfractions from microbial strains and perform research to find compounds; BioLeads also granted Schering an exclusive license to use such compounds to develop, produce and market drug products (9/26**)

Bioreason
Inc.*

Warner-
Lambert Co.
(subsidiary
of Pfizer Inc.)

Licensing agreement for Bioreason's software systems

ND

The software, DataPharmer, LeadPharmer and DrugPharmer, is designed to analyze data from high-throughput screening for drug discovery (9/21)

BioVex Ltd.
(UK)*

AstraZeneca
plc (UK)

Collaboration in the area of gene target validation

ND

AstraZeneca will evaluate the ability of BioVex's NeuroVEX vectors to efficiently transduce the cells and tissues of the nervous system in order to study the function of genes that may be viable targets for the therapy of neurodegenerative disorders (10/15)

Cambridge
Antibody
Technology
plc
(UK; CATG;
LSE:CAT)

Merck & Co.
Inc.

Five-year collaboration and license agreement for development of products for a target involved in HIV

ND

Merck will provide HIV biology work and CAT will provide its human phage antibody libraries; Merck gains exclusive rights to resulting products; CAT will receive an up-front technology access fee, milestones and potential royalties on the sale of products (10/10)

Cellomics
Inc.*

Wyeth-Ayerst
Laboratories (division of American Home Products Corp.)

Agreement to supply Cellomics' ArrayScan HCS technology

ND

Wyeth-Ayerst will use the technology in its research (11/14)

Ciphergen
Biosystems
Inc.
(CIPH)

Pfizer Inc.

Agreement to discover proteins in serum from rat models

ND

Agreement is also to evaluate the importance of such proteins as biomarkers associated with drug safety (10/8)

CombiMatrix
Corp.
(subsid-
iary of Acacia
Research Corp.;
ACRI)

Marubeni
Japan (Japan)

Joint venture focused on development and licensing opportunities for CombiMatrix's biochip technology

ND

The venture will focus on marketing and developing the technology for the Japanese market; Marubeni provided the funding for the operations and management team by acquiring a minority interest in the joint venture (10/29)

Corixa Corp.
(CRXA)

Amersham
Health (unit of
Amersham plc;
UK)

Bexxar

$25

Amersham Health will market Bexxar in Europe; the agreement calls for as much as $15M of Corixa stock to be purchased by Amersham, and an option for another $10M to be sold in the future at times chosen by Corixa (10/29)

CTI Tech-
nologies
Inc.
(subsidiary
of Cell Thera-
peutics Inc.;
CTIC)

Chugai Pharma-
ceutical Co. Ltd.
(Japan)

Licensing agreement for development and commercialization rights to PG-TXL in several Asian markets, including China, Malaysia, the Philippines and other countries

$73

CTI will get an up-front payment of $3M and milestone payments totaling $16M; another $54M will be paid by Chugai for development-related expenses (10/22)

Cytos Bio-
technology AG
(Switzerland)*

Novartis
Pharma AG
(Switzerland)

Research and license option agreements to develop therapeutic vaccines for allergy, rheumatoid arthritis and chronic nervous system disorders

CHF70
(US
$42.25)

If the option is exercised, Cytos will receive research funding and precommercialization milestone payments of up to US$42.25M, as well as sales royalties (10/23)

De Novo
Pharmaceu-
ticals
Ltd.
(UK)*

Roche Diag-
nostics Corp.
(division of
F. Hoffmann-
La Roche Ltd.;
Switzerland)

Technology development collaboration in the area of de novo drug design

ND

De Novo will retain full commercial rights of the design platform, Skelgen II; Roche will receive certain rights to use Skelgen II in drug discovery (10/16)

Dendreon
Corp.
(DNDN)

Bayer Corp.

Agreements to license two tumor antigens for use in Dendreon's therapeutic cancer vaccines

ND

The antigens are carcinoembryonic antigen and MN antigen (9/26)

Discovery
Partners
International
Inc.
(DPII)

Merck & Co.
Inc.

Multiyear agreement to design, develop and produce libraries of drug-like high-purity chemical compounds

ND

Discovery Partners will collaborate with Merck to develop custom compound libraries, then will manufacture and purify the compound using its high-speed purification technology (10/23)

DNA Sciences
Inc.*

Bristol-Myers
Squibb Co.

Partnership to investigate genetic variants within a potential gene target

ND

DNA Sciences will use its high-throughput sequencing and genotyping facility to study the BMS gene in normal and affected disease populations (10/9)

DoubleTwist
Inc.*

NV Organon
(the Nether-
lands)

Licensing agreement for the Prophecy database and tools suite, the Prophecy ToolKit and Genomatix Promoter Resource Database

ND

Prophecy will provide Organon access to DoubleTwist's annotated and assembled human genome database, as well as data mining and visualization tools (10/22)

Elitra Pharm-
aceuticals
Inc.*

Merck & Co.
Inc.

Collaboration in which Elitra will provide antibiotic targets that Merck will screen against its natural product and compound libraries

ND

Elitra will receive an up-front payment and will get three years of research funding, as well as milestone payments and royalties (10/25)

First Genetic
Trust Inc.*

GlaxoSmith-
Kline plc (UK)

Research collaboration to study genetic variations that influence why some patients experience certain adverse reactions when taking medications while others do not

ND

GlaxoSmithKline will conduct all analyses, while First Genetic Trust will provide secure genetic banking services, where biological samples and medical data can be stored (10/10)

Flamel Tech-
nologies
SA
(France; FLMLY)

Merck & Co.
Inc.

Licensing agreement for the application of Flamel's Micropump technology

ND

Merck will apply the technology to an undisclosed class of pharmaceutical compounds (10/10)

Galapagos
Genomics
NV
(Belgium)*

Pharmacia
Corp.

Functional genomics collaboration involving the use of Galapagos' PhenoSelect expression platform for gene target identification and validation applications

ND

Galapagos will construct a gene library for Pharmacia to identify and validate drug targets in a broad range of disease areas (11/14)

Galapagos
Genomics
NV
(Belgium)*

Procter &
Gamble Pharm-
aceuticals (unit of the Procter & Gamble Co.)

Collaboration under which P&G will use Galapagos' adenovirus technology as a tool to validate the utility of genes as new drug targets

ND

Galapagos will supply P&G with adenoviral vectors containing human genes selected by P&GP (10/22)

Genaissance
Pharmaceu-
ticals
Inc.
(GNSC)

Pfizer Inc.

Agreement to give Pfizer selected data from Genaissance's Hap Database

ND

The database is a collection of markers of gene variations, known as haplotypes (10/9)

Genencor
International
Inc.
(GCOR)

Dow Corning
Corp.

Agreement to mesh each company's knowledge in biotechnology and silicon chemistry to create a Silicon Biotechnology platform

$35

Dow will provide $12M up front, plus research funding and milestones, for a a total of about $35M (10/22)

Genicon
Sciences
Corp.*

Genomics
Institute of
the Novartis
Research
Foundation

Multiyear agreement to employ Genicon's Resonance Light Scattering technology for use in GNF's internal proteomic microarray research

ND

The two parties will collaborate to further develop and commercialize RLS technology in conjunction with GNF's proteomic microarray technologies for the discovery of new drugs and drug targets (11/1)

ImClone
Systems Inc.
(IMCL)

Bristol-Myers
Squibb Co.

Agreement to develop and promote IMC-225

$2B

ImClone will receive $200M at the signing of the deal, $300M when the BLA for IMC-225 is completed and submitted, and $500M upon FDA approval of the drug; Bristol-Myers also will buy about 14.4M shares of ImClone, for another $1B (9/19)

Immusol Inc.*

Novartis
Pharma AG
(Switzerland)

Five-year collaboration in which Immusol will deliver at least 50 targets to Novartis in the oncology area

$150

Immusol will use its Inverse Genomics technology to discover the targets; Novartis will then develop compounds; the deal is valued at $150M (10/1)

Inhale Thera-
peutic
Systems
Inc.
(INHL)

R.W. Johnson
Pharmaceutical Research Institute
and the Janssen
Research Foun-
dation (subsidi-
aries of Johnson
& Johnson)

Collaboration in which Inhale will use Inhance pulmonary delivery technology to develop formulations of inhaleable small-molecule compounds up to proof of concept

ND

R.W. Johnson and Janssen will evaluate and develop tested formulas; Inhale will receive research and development funding, milestone payments and royalty payments (10/10)

InterMune
Pharmaceu-
ticals
Inc.
(ITMN)

Eli Lilly &
Co.

Exclusive, worldwide rights agreement to develop, manufacture and commercialize oritavancin

$50

Lilly will receive $50M up front, as well as potential milestones and royalties on commercialized products; InterMune gets exclusive worldwide rights to develop, manufacture and commercialize oritavancin (9/20)

Invitrogen
Corp.
(IVGN)

American
Home Products
Corp.

Collaborative research service agreement for clones of genes

ND

Invitrogen will use its cDNA library and high-throughput gene isolation capabilities to provide full-length clones of genes targeted by Wyeth-Ayerst Laboratories (9/25)

Jerini AG
(Germany)*

Aventis Pharma
AG (Germany)

Product development and licensing agreement for the compound Icatibant

ND

Jerini gains exclusive, worldwide, royalty-bearing rights to develop Icabitant in human health treatment (11/13)

Kosan
Biosciences
Inc.
(KOSN)

Meiji Seika
Kaisha Ltd.
(Japan)

Research collaboration for Kosan's production of a polyketide in one of its hosts, and Kosan's development of a Meiji bacterium that produces a polyketide

ND

Meiji will provide funding for the one-year agreement (10/16)

Labopharm
Inc.
(Canada;
TSE:DDS)

Aventis Pharm-
aceuticals
(division of
Aventis Pharma
AG; Germany)

Global licensing agreement to incorporate Labopharm's controlled-release technology, Contramid, into Allegra

ND

Labopharm will receive milestone payments and will earn royalties on product sales of the new formulations (11/14)

Lexicon
Genetics Inc.
(LEXG)

Pfizer Inc.

Nonexclusive internal research licensing agreement

ND

Agreement for a patent covering the use of Lexicon's isogenic DNA technology in gene targeting (10/10)

Lexicon Pharm-
aceuticals
(unit of Lexicon
Genetics Inc.;
LEXG)

Pfizer Inc.

Agreement for nonexclusive use to a library of chemical compounds

ND

Pfizer will use the compounds in its internal drug discovery programs (9/26)

LifeSpan
BioSciences
Inc.*

Aventis Pharma
SA (France)

Agreement for access to a LifeSpan database

ND

Aventis became the sixth subscriber to LifeSpan's database on expression and localization of G protein-coupled receptors (10/9)

LifeSpan
BioSciences
Inc.*

Wyeth-Ayerst
Laboratories
(division of
American Home
Products Corp.)

Subscription agreement for LifeSpan's G protein- coupled receptor database

ND

Wyeth-Ayerst gains access to the database (11/13)

Maxygen Inc.
(MAXY)

Aventis Pasteur
(France; unit of
Aventis SA)

Three-year agreement to develop improved vaccines for a specific target

$60

Maxygen gets license fees, full research and development funding, minimum annual royalties, and potential milestone and royalty payments on product sales (11/5)

MediChem
Life
Sciences
Inc.
(MCLS)

Pharmacia
Corp.

Two-year medicinal chemistry agreement

ND

MediChem will commit resources for drug discovery in collaboration with Pharmacia's in-house researchers; MediChem will be paid for its research and will receive royalties on resulting products (10/9)

Morphotek
Inc.*

Wyeth-Ayerst
Laboratories
(unit of Ameri-
can Home
Products Corp.)

Collaborative research agreement to develop cell lines

ND

Morphotek will apply its Direct-Line technology for the development of cell lines for Wyeth's internal research and development programs in oncology (9/27)

Myriad
Genetics
Inc.
(MYGN)

Pharmacia
Corp.

Collaboration on a research project in pharmacogenomics

ND

The project is aimed at identifying genetic differences among individuals in the general population (10/30)

Nastech Pharm-
aceutical
Co.
Inc.
(NSTK)

G. Pohl
Boskamp
GmbH & Co.
(Germany)

Exclusive licensing agreement for development and European commercialization rights to Nastech's intranasal morphine for treatment of moderate to severe pain

ND

Nastech will receive an up-front licensing fee, milestone payments and double-digit royalties for achieving certain goals (9/26)

NeoOncoRx
Inc.
(unit of
NeoTherapeutics
Inc.; NEOT)

Bristol-Myers
Squibb Co.

Agreement to develop Elsamitrucin, which induces single-strand DNA breaks

ND

NeoOncoRx gains worldwide rights to develop and market the product (11/5)

Novelos
Therapeu-
tics Inc.*

HealthCare
Asia Pharma-
ceuticals Inc.
(Hong Kong)

Collaboration under which HealthCare Asia will develop and commercialize BAM-205

ND

BAM-205 will be developed to treat hepatitis B and C in China (10/23)

Orchid Bio-
Sciences Inc.
(ORCH)

GlaxoSmith-
Kline plc (UK)

Agreement to collaborate on a genome-wide validation of single nucleotide polymorphisms for pharmacogenetic studies

ND

Orchid will develop SNP assays and will conduct ultra-high-throughput genotyping analyses; GlaxoSmithKline will select SNP candidates from Orchid's design database (11/14)

Paladin Labs
Inc.
(Canada;
TSE:PLB)

Novartis
Pharmaceuticals
Canada Inc.

Rogitine

ND

Paladin acquired the Canadian rights to Rogitine, which is indicated to prevent and control hypertensive episodes in patients with pheochromocytoma (11/7)

Palatin Tech-
nologies Inc.
(AMEX:PTN)

Serono Pharma-
ceutical Research
Institute (unit of
Serono SA;
Switzerland)

Agreement in which Palatin will use Midas technology to generate compounds in support of Serono's research programs

ND

Financial details were not disclosed (10/1)

Pharmacopeia
Inc.
(PCOP)

Boehringer
Ingelheim
GmbH
(Germany)

Collaboration to provide Boehringer with tools to test compounds against an undisclosed target

ND

Pharmacopeia will provide assay development expertise, a multimillion-compound sample collection and ultra-high-throughput screening (10/2)

Progenics
Pharmaceu-
ticals
Inc. (PGNX)

UR Labs Inc.

Agreement for the rights to the pain-related drug methylnaltrexone

ND

The drug is entering Phase II trials; financial terms were not disclosed (10/1)

Rosetta Bio-
software
(unit
of Rosetta
Impharmatics
and Merck &
Inc. Co.)

GlaxoSmith-
Kline plc (UK)

Licensing agreement for the Rosetta Resolver Software Development Kit version 2.0

ND

The kit offers customers direct access to the system's open application program interfaces (10/8)

Quark Biotech
Inc.*

AstraZeneca
plc (UK)

Collaborative agreement focusing on a search for cancer drug targets using QBI's BiFar technology

ND

QBI is providing 100 genes/proteins to AstraZeneca, and they will validate those that are functional; AstraZeneca will have the right to select and license a certain number of target genes and proteins for development, and it will have exclusive worldwide rights to commercialize products generated from the collaboration (10/3)

Sequitur
Inc.*

Procter &
Gamble Pharm-
aceuticals Co.
(unit of the
Procter &
Gamble Co.)

Agreement giving P&G access to Sequitur's functional genomics technology

ND

Sequitur will perform biological screening and provide its antisense methods and compounds to P&G target validation studies (10/9)

SomaLogic*

Mitsui & Co.
Ltd. (Japan)

Collaboration to identify potential aptamer customers in Asia

ND

Mitsui gained Asian rights to sell aptamers for certain proteomics applications; Mitsui also made an equity investment in SomaLogic (11/6)

Sunesis Pharm-
aceuticals
Inc.*

Chiesi Farm-
aceutici S.p.A.
(Italy)

Research collaboration to discover and develop small molecules that inhibit a well-validated protein- protein target involved in immunological diseases

$22-
$30

Sunesis will receive up-front payments, research and development milestones and royalty payments based on sales; Chiesi will have an exclusive option to an exclusive license to develop and market any resulting products in Europe and Latin America; deal could be worth between $22M and $30M (10/10)

Targesome
Inc.*

Merck KGaA
(Germany)

Research and collaboration agreement in which the companies will evaluate the potential of combining Merck's small-molecule antiangiogenesis compounds with Targesome's nanoparticle technology

ND

The companies will look at the potential for the making of new drugs for cancer and macular degeneration; the companies may enter into a collaboration to develop any drugs that come out of the research phase (10/23)

Tripos Inc.
(TRPS)

AstraZeneca
plc (UK)

Multiyear, multimillion- dollar agreement to provide the Sybyl suite of in silico drug discovery software technologies

ND

The relationship will enable searching of databases to locate possible drug candidates, perform virtual testing of candidates and guide scientists seeking to improve the effectiveness of the best candidates (9/20)

Valentis Inc.
(VLTS)

Pfizer Inc.

Nonexclusive license for Valentis' GeneSwitch gene regulation technology

ND

The license is for research purposes only (10/23)

Vysis Inc.
(VYSI)

Roche Diag-
nostics Corp.
(unit of F.
Hoffmann-La
Roche Ltd.;
Switzerland)

Exclusive license agreement that will provide Vysis access to genetic markers

ND

The markers may allow for the unique identification of fetal cells in a maternal blood sample (9/25)

Weston Medi-
cal Group
plc
(UK; LSE:
WMG)

Chugai Pharm-
aceutical Co.
Ltd. (Japan)

Option and licensing agreement giving Chugai access to Weston's Intraject needle-free drug delivery technology for the administration of an undisclosed therapeutic product

ND

Weston will receive an up-front fee and milestone payments, as well as potential royalties (10/8)

Wilex AG
(Germany)*

Bayer AG
(Germany)

License, sublicense and option agreement with Bayer's diagnostics group to obtain certain rights under Bayer's MN patent portfolio

ND

Wilex receives certain intellectual property rights that protect its G250 antibody; Bayer also granted to Wilex option rights to develop certain other antibodies targeting the MN antigen, as well as certain diagnostic option rights (11/12)

Xerion Pharma-
ceuticals
AG
(Germany)*

Byk Gulden
(unit of Altana
AG; Germany)

Target validation agreement

ND

Xerion will use its XCALIbur technology for analysis; Byk Gulden will provide target proteins important to diseases such as cancer and inflammation (10/26)


NOTES

# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the Nasdaq market.

** Denotes the date the item ran in BioWorld International.

ND = Not disclosed, reported and/or available

AMEX = American Stock Exchange; LSE = London Stock Exchange; TSE = Toronto Stock Exchange